TTF is a non-invasive cancer therapy that uses low-intensity, intermediate-frequency alternating electric fields to disrupt the division of cancer cells. It is often considered the “fourth modality” in cancer treatment, alongside surgery, radiotherapy, and pharmacotherapy (chemotherapy and immunotherapy).

Cancer cells divide rapidly through a process called mitosis. During this process, charged proteins such as tubulin align to form the mitotic spindle, which separates chromosomes. TTF generates specific electric fields that interfere with these proteins, preventing spindle formation. This disruption halts cell division and can trigger cancer cell death, while sparing healthy, non-dividing cells.

Our system is designed to maximize the therapeutic field delivered to the tumor while minimizing exposure to surrounding healthy tissue.
Key benefits include: Enhanced therapeutic effect: More precise and potent targeting of cancer cells.
Optimized patient experience: Better control of treatment parameters to improve comfort and reduce side effects, such as skin irritation.

We plan to initiate clinical trials in 2026.